Tumor heterogeneity is a term that refers to differences between tumors of the same type in distinct patients as well as to differences observed between cells within a tumor. The later is known as intratumoral heterogeneity (ITH) and is of high clinical relevance, since it directly affects the robustness of prognostic, diagnostics and prediction of biomarkers. Up to date ITH has been mainly investigated at the genomic level. Sequencing of multiple regions from the same cancer specimen have revealed that within a single tumor several clones of cells with distinct mutational landscapes exist, likely as a consequence of clonal evolution. However, ITH can also be driven by differences in the microenvironment that may rather be reflected ...
We performed a proteogenomic analysis of hepatocellular carcinomas (HCCs) across clinical stages and...
AbstractHepatocellular carcinoma (HCC) has been ranked as the third leading cause of cancer-related ...
Complicating proteomic analysis of whole tissues is the obvious problem of cell heterogeneity in tis...
The interpatient variability of tumor proteomes has been investigated on a large scale but many tumo...
<p>Intra-tumor heterogeneity (ITH) has been characterized at the morphologic and genomic level. Howe...
It remains unclear to what extent tumor heterogeneity impacts on protein biomarker discovery. Here, ...
Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by pr...
Normal adjacent tissues (NATs) of hepatocellular carcinoma (HCC) differ from healthy liver tissues a...
Introduction: Recent studies indicated tumors may be comprised of heterogeneous molecular subtypes a...
Introduction: Recent studies indicated tumors may be comprised of heterogeneous molecular subtypes a...
MS-based proteomics has been applied to a differential network analysis of the nuclear-cytoplasmic s...
Morphologic heterogeneity within an individual tumor is well-recognized by histopathologists in surg...
Introduction : Tumor heterogeneity is a major obstacle for developing effective anti-cancer treatmen...
A new workflow for protein-based tumor heterogeneity probing in tissues is here presented. Tumor het...
We performed a proteogenomic analysis of hepatocellular carcinomas (HCCs) across clinical stages and...
AbstractHepatocellular carcinoma (HCC) has been ranked as the third leading cause of cancer-related ...
Complicating proteomic analysis of whole tissues is the obvious problem of cell heterogeneity in tis...
The interpatient variability of tumor proteomes has been investigated on a large scale but many tumo...
<p>Intra-tumor heterogeneity (ITH) has been characterized at the morphologic and genomic level. Howe...
It remains unclear to what extent tumor heterogeneity impacts on protein biomarker discovery. Here, ...
Current manuscript gives a synopsis of tumor heterogeneity related to patient samples analyzed by pr...
Normal adjacent tissues (NATs) of hepatocellular carcinoma (HCC) differ from healthy liver tissues a...
Introduction: Recent studies indicated tumors may be comprised of heterogeneous molecular subtypes a...
Introduction: Recent studies indicated tumors may be comprised of heterogeneous molecular subtypes a...
MS-based proteomics has been applied to a differential network analysis of the nuclear-cytoplasmic s...
Morphologic heterogeneity within an individual tumor is well-recognized by histopathologists in surg...
Introduction : Tumor heterogeneity is a major obstacle for developing effective anti-cancer treatmen...
A new workflow for protein-based tumor heterogeneity probing in tissues is here presented. Tumor het...
We performed a proteogenomic analysis of hepatocellular carcinomas (HCCs) across clinical stages and...
AbstractHepatocellular carcinoma (HCC) has been ranked as the third leading cause of cancer-related ...
Complicating proteomic analysis of whole tissues is the obvious problem of cell heterogeneity in tis...